313 related articles for article (PubMed ID: 32033781)
41. Reappraisal of PLA2R1 in membranous nephropathy: immunostaining method influence and association with IgG4-dominant phenotype.
Hara S; Goto S; Kamiura N; Yoshimoto A; Naito T; Imagawa N; Imai Y; Yanagita M; Nishi S; Itoh T
Virchows Arch; 2015 Jul; 467(1):87-94. PubMed ID: 25820371
[TBL] [Abstract][Full Text] [Related]
42. [Idiopathic and secondary membranous nephropathies].
Ronco P; Debiec H
Presse Med; 2012 Mar; 41(3 Pt 1):290-7. PubMed ID: 22208961
[TBL] [Abstract][Full Text] [Related]
43. Pathogenesis of membranous nephropathy: a new paradigm in evolution.
Glassock RJ
Contrib Nephrol; 2013; 181():131-42. PubMed ID: 23689575
[TBL] [Abstract][Full Text] [Related]
44. Contactin-1 is a novel target antigen in membranous nephropathy associated with chronic inflammatory demyelinating polyneuropathy.
Le Quintrec M; Teisseyre M; Bec N; Delmont E; Szwarc I; Perrochia H; Machet MC; Chauvin A; Mavroudakis N; Taieb G; Lanfranco L; Rigothier C; José B; Concetta C; Geneste C; Pernin V; Larroque C; Devaux J; Beyze A
Kidney Int; 2021 Dec; 100(6):1240-1249. PubMed ID: 34600965
[TBL] [Abstract][Full Text] [Related]
45. Interaction between PLA2R1 and HLA-DQA1 variants contributes to the increased genetic susceptibility to membranous nephropathy in Western China.
Wang W; Fan S; Li G; Wang AY; Hong D; Zhong X; Wang L
Nephrology (Carlton); 2019 Sep; 24(9):919-925. PubMed ID: 30467913
[TBL] [Abstract][Full Text] [Related]
46. Clinical significance of M
Gong Z; Yuan S; Zhu X; Wang Y; Yu F; Yang D; Xu X; Liu H; Li J; Sun L
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2020 Jun; 45(6):693-700. PubMed ID: 32879127
[TBL] [Abstract][Full Text] [Related]
47. Current insights into functions of phospholipase A2 receptor in normal and cancer cells: More questions than answers.
Sukocheva O; Menschikowski M; Hagelgans A; Yarla NS; Siegert G; Reddanna P; Bishayee A
Semin Cancer Biol; 2019 Jun; 56():116-127. PubMed ID: 29104026
[TBL] [Abstract][Full Text] [Related]
48. A case of membranous nephropathy characterized by atypical distribution of phospholipase A2 receptor
.
Hyodo T; Saito K; Kono K; Nishi S; Itoh T; Hara S
Clin Nephrol; 2019 Feb; 91(2):114-119. PubMed ID: 30474595
[TBL] [Abstract][Full Text] [Related]
49. Generation of a conditional transgenic mouse model expressing human Phospholipase A2 Receptor 1.
Jaber S; Goehrig D; Bertolino P; Massemin A; Bihl F; Chabry J; Lambeau G; Vindrieux D; Bernard D
Sci Rep; 2020 May; 10(1):8190. PubMed ID: 32424163
[TBL] [Abstract][Full Text] [Related]
50. PLA2R1 and HLA-DQA1 gene variations in idiopathic membranous nephropathy in South China.
Wang F; Wang TT; Liang XW; Lu JD; Xie QH; Chen RY; Xue J
Ann Acad Med Singap; 2021 Jan; 50(1):33-41. PubMed ID: 33623956
[TBL] [Abstract][Full Text] [Related]
51. Serum with phospholipase A2 receptor autoantibodies interferes with podocyte adhesion to collagen.
Škoberne A; Behnert A; Teng B; Fritzler MJ; Schiffer L; Pajek J; Lindič J; Haller H; Schiffer M
Eur J Clin Invest; 2014 Aug; 44(8):753-65. PubMed ID: 24942189
[TBL] [Abstract][Full Text] [Related]
52. sPLA2-IB and PLA2R mediate insufficient autophagy and contribute to podocyte injury in idiopathic membranous nephropathy by activation of the p38MAPK/mTOR/ULK1
Yang L; Wu Y; Lin S; Dai B; Chen H; Tao X; Li G; Wan J; Pan Y
FASEB J; 2021 Feb; 35(2):e21170. PubMed ID: 33184968
[TBL] [Abstract][Full Text] [Related]
53. HLA-DQA1 and PLA2R1 polymorphisms and risk of idiopathic membranous nephropathy.
Bullich G; Ballarín J; Oliver A; Ayasreh N; Silva I; Santín S; Díaz-Encarnación MM; Torra R; Ars E
Clin J Am Soc Nephrol; 2014 Feb; 9(2):335-43. PubMed ID: 24262501
[TBL] [Abstract][Full Text] [Related]
54. Evaluation of anti-PLA2R1 as measured by a novel ELISA in patients with idiopathic membranous nephropathy: a cohort study.
Timmermans SA; Damoiseaux JG; Heerings-Rewinkel PT; Ayalon R; Beck LH; Schlumberger W; Salant DJ; van Paassen P; Tervaert JW;
Am J Clin Pathol; 2014 Jul; 142(1):29-34. PubMed ID: 24926082
[TBL] [Abstract][Full Text] [Related]
55. Successful treatment of PLA
Schmidt T; Schulze M; Harendza S; Hoxha E
J Nephrol; 2021 Apr; 34(2):603-606. PubMed ID: 33026632
[TBL] [Abstract][Full Text] [Related]
56. [Detection of PLA2R1 in renal biopsy specimens of patients with idiopathic membranous nephropathy].
Zhu SS; Zhou SL; Zhou CM; Li YQ; Zou HQ
Nan Fang Yi Ke Da Xue Xue Bao; 2015 Apr; 35(4):526-9. PubMed ID: 25907937
[TBL] [Abstract][Full Text] [Related]
57. Membranous Nephropathy: A Journey From Bench to Bedside.
Francis JM; Beck LH; Salant DJ
Am J Kidney Dis; 2016 Jul; 68(1):138-47. PubMed ID: 27085376
[TBL] [Abstract][Full Text] [Related]
58. Course monitoring of membranous nephropathy: Both autoantibodies and podocytes require multidimensional attention.
Liu W; Huang G; Rui H; Geng J; Hu H; Huang Y; Huo G; Liu B; Xu A
Autoimmun Rev; 2022 Feb; 21(2):102976. PubMed ID: 34757091
[TBL] [Abstract][Full Text] [Related]
59. [New physiopathological roles for the PLA2R1 receptor in cancer and membranous nephropathy].
Girard CA; Seitz-Polski B; Dolla G; Augert A; Vindrieux D; Bernard D; Lambeau G
Med Sci (Paris); 2014 May; 30(5):519-25. PubMed ID: 24939538
[TBL] [Abstract][Full Text] [Related]
60. Novel ELISA for thrombospondin type 1 domain-containing 7A autoantibodies in membranous nephropathy.
Zaghrini C; Seitz-Polski B; Justino J; Dolla G; Payré C; Jourde-Chiche N; Van de Logt AE; Booth C; Rigby E; Lonnbro-Widgren J; Nystrom J; Mariat C; Cui Z; Wetzels JFM; Ghiggeri G; Beck LH; Ronco P; Debiec H; Lambeau G
Kidney Int; 2019 Mar; 95(3):666-679. PubMed ID: 30784662
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
